首页|病原宏基因二代测序在恶性血液肿瘤中的应用进展

病原宏基因二代测序在恶性血液肿瘤中的应用进展

扫码查看
病原宏基因二代测序(metagenomic next-generation sequencing,mNGS)是一种新兴的病原学检测方法,能够快速、无差异、无偏倚地对标本中所有微生物进行测序,从而显著提高了病原微生物的检出率.恶性血液肿瘤并发感染具有较高的发病率和病死率,并且其感染类型及致病微生物复杂多样,给临床诊断带来一定困难.针对不同类型的恶性血液肿瘤伴感染,mNGS都具备较高的临床诊断价值.本文综述了mNGS技术目前在恶性血液肿瘤中的应用现状及局限性,以期推动该技术在恶性血液肿瘤伴感染方面更好地应用.
Research progress of metagenomic next-generation sequencing in detecting infectious pathogens in patients with haematological malignancies
Metagenomic next-generation sequencing(mNGS)is an emerging pathogen detection method,which can rapidly,uniformly and unbiased sequence all microorganisms in a specimen,thus significantly improving the detection rate of pathogenic microorganisms.Hematological malignancies complicated with infection have high morbidity and mortality,and the types of infection and pathogenic microorganisms are complex and diverse,which bring certain difficulties to clinical diagnosis.mNGS has high clinical diagnostic value for different types of hematological malignancies with infection.This paper reviews the current application status and limitations of mNGS technology in hematological malignancies,in order to promote the better application of this technology in hematological malignancies with infection.

mNGShematological malignancieshematopoietic stem cell transplantationfebrile neutropenia

王艳琼、彭苗新、欧阳建

展开 >

南京医科大学鼓楼临床医学院血液科,南京 210008

南京大学医学院附属鼓楼医院血液科,南京 210008

宏基因二代测序 恶性血液肿瘤 造血干细胞移植 中性粒细胞缺乏伴发热

南京大学医学院附属鼓楼医院临床试验研究面上项目

2021-LCYJ-MS-19

2023

生命的化学
中国生物化学与分子生物学会

生命的化学

CSTPCD
影响因子:0.404
ISSN:1000-1336
年,卷(期):2023.43(10)
  • 4